Physician profile
Elizabeth Philippe
NPI 1639238488
$3,057.39
in general payments reported to CMS, 2019-2025
30 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $128 · 2021: $357 · 2022: $652 · 2023: $664 · 2024: $409 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $537.45 | 2022-2024 | Minimed 780g, Minimed 770g |
| Boston Scientific Corporation | $473.48 | 2019-2025 | Watchman Flx |
| Gilead Sciences, INC. | $391.44 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $308.11 | 2019-2025 | Dovato, Apretude |
| Astrazeneca Pharmaceuticals LP | $181.72 | 2019-2024 | Airsupra, Farxiga |
| Coloplast Corp | $166.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $141.14 | 2020-2025 | Invega Sustenna |
| Inspire Medical Systems, INC. | $132.05 | 2023 | Inspire |
| Abbvie INC. | $90.86 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $59.74 | 2021-2024 | Austedo Xr |
| Abbott Laboratories | $52.44 | 2022 | |
| Janssen Biotech, INC. | $49.72 | 2019-2022 | |
| Corcept Therapeutics | $47.19 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $46.75 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.85 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $39.60 | 2025 | Nuvision Ice Catheter, Carto 3 |
| Indivior INC. | $32.77 | 2021 | |
| Neurocrine Biosciences, INC. | $30.57 | 2025 | |
| Insulet Corporation | $29.56 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $22.92 | 2025 | Voquezna |
| Cequr Corporation | $22.61 | 2024 | Cequr Simplicity |
| Vbi Vaccine (Delaware) INC. | $21.88 | 2023 | Prehevbrio |
| Sanofi Pasteur INC. | $20.00 | 2023 | |
| Exact Sciences Corporation | $19.96 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $18.37 | 2023 | Gardasil 9, M-M-R II, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $18.02 | 2020 | |
| Radius Health, INC. | $16.50 | 2020 | |
| Alkermes, INC. | $15.65 | 2025 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2021 | |
| Pfizer INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Philippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.